Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 30, 2023, titled "Zydus and Sun Pharma sign licensing agreement for co-marketing of Desidustat, a critical treatment for Chronic Kidney Disease patients in India".
Press Release Oct 30 2023
Filed with NSE · · 5 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced a licensing agreement with Sun Pharma for co-marketing Desidustat, an innovative oral treatment for anemia associated with Chronic Kidney Disease in India. Under this agreement, Sun Pharma will market the drug as RYTSTAT while Zydus will continue to market it as Oxemia™. Zydus will receive upfront licensing income and milestone payments based on specific achievements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Oct 25 2023
- Press Release Oct 20 2023
- Press Release Oct 16 2023
- Press Release Oct 06 2023
- Press Release Sep 29 2023
Later from Zydus Lifesciences
- Press Release Oct 31 2023
- Press Release Nov 02 2023
- Press Release Nov 03 2023
- Zydus Lifesciences Limited Press Release Nov 06 2023
- Press Release Nov 07 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences